By Fineline Cube 
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today released its third‑quarter 2025 financial results. Operating revenue rose RMB 637 million, a 31.4 % year‑on‑year increase. For the first nine months of 2025, total revenue reached RMB 1.806 billion, up 42.06 % YoY.
Highlights
| Metric | Q3 2025 | YoY Change |
|---|---|---|
| Operating Revenue | RMB 637 million | +31.4 % |
| 9‑Month Revenue | RMB 1.806 billion | +42.06 % |
| Cash & Cash‑Equivalents (End‑of‑Period) | RMB 3.270 billion | – |
Revenue Drivers
- Toripalimab (LOQTORZI, JS001) sold ≈ RMB 1.495 billion in the domestic Chinese market, up ~40 % YoY.
- Net loss narrowed significantly versus the same period in 2024.
Regulatory Milestones
- NMPA accepted a supplemental New Drug Application (sNDA) for toripalimab as first‑line therapy in HER2‑expressing urothelial carcinoma.
- 12 indications approved in mainland China; 10 listed on China’s National Reimbursement Drug List (NRDL).
- Toripalimab approved in > 40 countries/regions (incl. U.S., EU, India, U.K., Australia, Canada, UAE, etc.) and is under review in multiple other markets.
Pipeline & Clinical Development
| Asset | Development Stage | Target Indication | Regulatory Status |
|---|---|---|---|
| JS207 (PD‑1/VEGF bispecific) | Phase II/III | Neoadjuvant NSCLC | FDA IND approved |
| JS005 (Anti‑IL‑17A mAb) | Phase III | Moderate‑to‑severe plaque psoriasis | Primary endpoint met |
| JT118 (Monkeypox vaccine) | Phase I/II | Monkeypox | NMPA CTA approved |
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech